Dr. Melton: To me, the term “mucoadhesive” translates into a drop that might blur vision. Yet, if you look at the two Phase III studies, zero patients out of 203 in the first study and zero patients out of 206 in the second study had drug-related blurred vision, and that's on the active drug, which is pretty remarkable. 3–5 This has clinically been supported by my own experience putting patients on LE gel and not getting any negative feedback regarding blurred vision. It's a pretty viscous, mucoadhesive drop, and because of its adaptive viscosity characteristics, it is unique as a gel.
Prolonged use may result in glaucoma , with damage to the optic nerve , defects in visual acuity and fields of vision, and posterior subcapsular cataract formation. Prolonged use may suppress the host response and thus increase the hazard of secondary ocular infections. In those diseases causing thinning of the cornea or sclera , perforations have been known to occur with the use of topical steroids. In acute purulent conditions of the eye, steroids may mask infection or enhance existing infection. If this product is used for 10 days or longer, intraocular pressure should be routinely monitored even though it may be difficult in children and uncooperative patients.
Neuropsychiatric: A wide range of psychiatric reactions including affective disorders (such as irritable, euphoric, depressed and labile mood, and suicidal thoughts), psychotic reactions (including mania, delusions, hallucinations, and aggravation of schizophrenia), marked euphoria leading to dependence; aggravation of epilepsy, behavioural disturbances, irritability, nervousness, anxiety, sleep disturbances, and cognitive dysfunction including confusion and amnesia have been reported. Reactions are common and may occur in both adults and children. In adults, the frequency of severe reactions has been estimated to be 5-6%. Psychological effects have been reported on withdrawal of corticosteroids; the frequency is unknown.